PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study

Author(s):  
Clara G. Chisari ◽  
Giancarlo Comi ◽  
Massimo Filippi ◽  
Damiano Paolicelli ◽  
Pietro Iaffaldano ◽  
...  
2009 ◽  
Vol 36 (S 02) ◽  
Author(s):  
A Hahn ◽  
T Schmidt-Wilcke ◽  
S Prügl ◽  
G Schuierer ◽  
U Bogdahn ◽  
...  

2021 ◽  
Author(s):  
Nikos Evangelou ◽  
Afagh Garjani ◽  
Sameer Patel ◽  
Dhiren Bharkhada ◽  
Waqar Rashid ◽  
...  

Abstract This study aimed to understand changes in the risk of SARS-CoV-2 infection among all people with multiple sclerosis (MS) receiving immunomodulatory disease-modifying therapies (DMTs) in England, compared to the general population, following mass vaccination. Longitudinal data collected by the National Health Service (NHS) England on all MS DMT prescriptions and the UK Health Security Agency on all registered SARS-CoV-2 test results were analysed. The incidence rate ratio of SARS-CoV-2 infection among people with MS taking DMTs compared to the general population was calculated before (November 2020-January 2021) and after (July-August 2021) mass vaccination. Risk of SARS-CoV-2 infection among people on ocrelizumab or fingolimod compared to the general population increased following liberalisation of COVID-19 restrictions (during March-July 2021) despite mass vaccination. No changes were found with other DMTs. These findings converge with the impaired immune response to vaccines observed with ocrelizumab and fingolimod.


Author(s):  
Elisa Bribiesca-Contreras ◽  
Christian García-Estrada ◽  
Enrique Gómez-Figueroa ◽  
Lizeth Zertuche-Ortuño ◽  
Roberto Rodríguez-Rivas ◽  
...  

2020 ◽  
Vol 45 ◽  
pp. 102360 ◽  
Author(s):  
T. Heinonen ◽  
E. Castrén ◽  
T. Luukkaala ◽  
K. Mäkinen ◽  
J. Ruutiainen ◽  
...  

2019 ◽  
Vol 26 (8) ◽  
pp. 902-911 ◽  
Author(s):  
Julie Yoon Moberg ◽  
Bjarne Laursen ◽  
Lau Caspar Thygesen ◽  
Melinda Magyari

Background: A diagnosis of multiple sclerosis (MS) may impact the choice of parenthood. Objective: To investigate the number of live births, abortions and ectopic pregnancies among persons with MS. Methods: From the Danish Multiple Sclerosis Registry, we extracted data from all persons diagnosed with MS from 1960 to 1996 and matched each MS person with four reference persons. We used a negative binomial regression model for the live births and Poisson regression model for abortions and ectopic pregnancies. The total fertility rate (TFR) during 1960–2016 and the annual number of live births in the MS population were analysed. Results: Persons with MS had fewer children than reference persons. Fewer women with MS had elective abortions after diagnosis (incidence rate ratio (IRR) = 0.88; 95% confidence interval (CI) = 0.78–1.00) than reference persons. There was no difference regarding the number of elective abortions, spontaneous abortions or ectopic pregnancies after onset. The TFR was lower for women with MS than for reference persons, and the number of annual live births by MS persons increased during 1960–2016. Conclusion: MS seems to considerably impact reproductive choices, especially after clinical diagnosis, resulting in the MS population having fewer children than the general population.


Author(s):  
Gorica D. Maric ◽  
Tatjana D. Pekmezovic ◽  
Sarlota T. Mesaros ◽  
Olivera S. Tamas ◽  
Jovana B. Ivanovic ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document